# Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease

> **NCT07292012** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives** · enrollment: 110 (estimated)

## Conditions studied

- Crohn Disease (CD)

## Interventions

- **DRUG:** Mirikizumab - IV
- **DRUG:** Mirikizumab - SC

## Key facts

- **NCT ID:** NCT07292012
- **Lead sponsor:** Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2027-07
- **Final completion:** 2029-01
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07292012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07292012, "Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07292012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*